Clinical Trial Update: Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal [Phase 2]

View source ↗

Summary

Phase IIa study of AV411 (ibudilast), a glial activation inhibitor, for opioid withdrawal has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• AV411

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Opioid-Related Disorders | Phase 2 | Status: COMPLETED | Results posted: 2016-12-05